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Abstract
Quantum mechanical theories are used to search and optimize
the conformations of proposed small molecule candidates for treat-
ment of SARS-CoV-2. These candidate compounds are taken
from what is reported in the news and in other pre-peer-reviewed
literature (e.g. ChemRxiv, bioRxiv). The goal herein is to provide
predicted structures and relative conformational stabilities for se-
lected drugs and ligands, in the hopes that other research groups
can make use of them for developing a treatment. The following
six compounds are investigated: chloroquine, hydroxychloro-
quine, remdesivir, eriodictyol, silmitasertib and valproic acid.
Initial exploration for conformations are performed at the HF/6-
31G(d)//HF/6-31G(d) theory level, which are then further op-
timized at more rigorous theory levels (e.g. B97-D3(BJ)/cc-
pVTZ//B97-D3(BJ)/cc-pVTZ). The resulting structures are made
available via GitHub.
Please note that we are not advocating that the compounds
focused herein should be used as medical treatments for the SARS-
CoV-2. Instead we are simply providing predicted conformations
and relative energies of compounds that can be used for further
research purposes.
Introduction
Across the world researchers are focused upon finding a drug
treatment for the Coronavirus Disease-2019 (SARS-CoV-2). Log-
ically, much of the focus is repurposing approved drugs, followed
by those that are in drug development pipeline. Repurposing drugs
is a much quicker endeavor than discovering new ones since their
chemical optimization, toxicology profiling, clinical trials and bulk
manufacturing are already in place [1]. Several research groups
have already proposed possible candidates for testing [2–7]. The
results of this testing could provide a spectrum of outcomes - rang-
ing from a compound that show high promise for use in patient
treatment to very little activity. However, hindering some our un-
derstanding will be the lack of three-dimensional (3D) knowledge
of the drugs’ structures and their conformations.
Promiscuity underlies the concept of drug repurposing [8–13].
A promiscuous drug (i.e. ligand) implies that it is structurally and
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chemically complementary to several receptor, while a promiscu-
ous receptor implies that several ligands possess high similarity.
Limiting our ability to exploit ligand similarity for repurposing are
the difficulties to experimentally elucidate or theoretically predict
3D conformations and their electrostatic profiles. This difficulty
arises from the dynamic nature of molecules and their complex
multidimensional potential energy surface [14]. Affirming this is
the fact that only a fraction of the 1634 approved small-molecule
drugs [15] have a single 3D conformation resolved.
Herein, the 3D structures of the top candidates for SARS-CoV-2
treatment are computed using quantum mechanical (QM) theo-
ries, starting with chloroquine since it is already being tested
in hospitals and proceeding to other approved drugs according
to Table 1 in reference [4]. An semi-extensive conformational
search is performed for each molecule in hopes that the low en-
ergy conformations are well represented. Since this work is ongo-
ing, we provide the coordinates of the conformations via GitHub
(https://github.com/karlkirschner/SARS-CoV-2-3D-Structures) to
allow other researchers immediate access to the data.
Partial Atomic Charges While not the current focus, partial
atomic charges for these structures can also be determined rela-
tively quickly using the AM1-BCC or RESP methodologies. If
you would like to have partial atomic charges computed for a cer-
tain compound (e.g. for use in MD simulation, docking, similarity
calculations) please contact the corresponding author (KNK).
Methodology
Initial structures were obtained from the Protein Data Bank [16]
when an experimentally determined geometry is available, or from
ChemPub [17]. Full geometry optimizations were performed
at the HF/6-31G(d)//HF/6-31G(d) theory level. Optimizations
at more rigorous theory levels will be performed (e.g. B97-
D3(BJ)/cc-pVTZ and MP2/cc-pVTZ) as time allows. The B97-
D3(BJ) [18–20] is believed to be a fairly reliable density func-
tional approximation (i.e. GGA+dispersion) for computing ge-
ometries [21] and energetics [22]. Frequencies calculations were
performed on selected minima using finite-differences of gradients
at the same theory level reported for the relative energies.
Initial 3D structure generation:
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• chlorpromazine [23, 24] (initial structure: 5g08 X-ray): 2
puckering conformations
• chloroquine [25] (model building): 2 configurational
stereoisomer
• hydroxychloroquine (model building using chloroquine’s re-
sults): 2 configurational stereoisomer
• remdesivir [26] (model building): single topology
• eriodictyol [27] (initial structure: ERD X-ray): 2 envelope
conformations
• silmitasertib [28] (initial structure: 3NGA X-ray): single
topology
• valproic acid [29]: (initial structure: 1DIT X-ray): single
topology
All QM calculations were done using Psi4 (v. 1.1a2.dev170)
[30]. Figures were created using PyMol [31], Python3, Matplotlib
[32] and Inkscape.
Results and Discussion
The HF/6-31G(d)//HF/6-31G(d) theory level performs fairly
well for generating optimized geometries and is relatively inex-
pensive with regards to computational cost. The use of this theory
allows for a quick survey of the possible conformations that a
given molecule might have. However, past experience has shown
that it often over predicts the number of minima in comparison
to an electron-correlated theory level using a larger basis set (e.g.
B97-D3(BJ)/cc-pVTZ, MP2/cc-pVTZ). Due to the quick need of
structural data, a majority of the initial calculations were done at
HF/6-31G(d)//HF/6-31G(d) theory level.However, optimizations
are continually being completed at more rigorous theory levels.
Once completed and made available, these geometries should
preferentially be considered.
All currently optimized geometries can be obtained follow-
ing the GitHub link mentioned in the Introduction. Each xyz-
formatted file contains all of the optimized conformations, ordered
from most- to least-stable conformation.
The relative energies for a given molecule (and isomer when rel-
evant) are provided in Tables 1–4. Concerning relative stability of
the conformations, HF/6-31G(d)//HF/6-31G(d) is able to provide a
very general ordering of the predicted relative energies. However,
including electron correlation into the calculations with at least a
triple-zeta basis set is required for more reliable predictions of rel-
ative energies. As time allows, more refined optimizations will be
performed using more rigorous theory levels (e.g. B97-D3(BJ)/cc-
pVTZ). The tables within the body of the manuscript represent
the most rigorous theory levels currently computed, while the SI
material will contain data computed at lower theory levels.
It should be noted that these geometries and relative energies
are computed in the gas-phase at a temperature that is consid-
ered to be 0 K. Consequently, these results cannot be directly
transferred to how the compounds behave at body temperature
and under physiological conditions. There are other theoretical
methods that are better for considering what conformations ligand
adopt upon interacting with binding sites, for example molecular
dynamics (MD) calculations. Never-the-less, the results herein
provide a starting point for understanding their possible conforma-
tional space, incorporating these compounds into MD models and
correlating their 3D structures to other observables (e.g. similarity
calculations).
Chloroquine Chloroquine and its close analogue hydroxy-
chloroquine has been mentioned in the news frequently as a possi-
ble drug to repurpose for treating coronavirus patients. However,
several studies have shown that these drugs can cause dangerous
heart rhythm, resulting in the U.S Food and Drug Administration
issuing a warning [33, 34].
Chloroquine and hydroxychloroquine have an stereogenic sp3
carbon atom in a central location of the molecules (Figure 1). It is
unclear in our survey of the literature if it is known which stereoiso-
mer is the preferentially active one, or if both are. Consequently,
both stereoisomers were investigated, with B97-D3(BJ)/cc-pVTZ
identifying over 100 unique stationary points for each isomer
whose relative energies range up to 16.5 kcal·mol−1 (Tables 1 and
2). Only three and two conformations of chloroquine isomers 1
and 2 possessed relative energies below 2.0 kcal·mol−1.
Hydroxychloroquine Isomer1 This drug is highly flexible and
it is likely that a near complete identification of possible confor-
mations was not made. Never-the-less, 265 unique conformations
were optimized at the B97-D3(BJ)/cc-pVTZ theory level. In addi-
tion to the intramolecular hydrogen bond that is formed between
the acyclic nitrogens (as found in chloroquine, see Figure 1a and
b), this theory level predicts that the unique terminal hydroxyl
group forms an intramolecular interaction with the conjugated
rings system (e.g. conformer 1). Five conformations have relative
energies below 2.0 kcal·mol−1, with an additional ten conforma-
tion below 3.0 kcal·mol−1.
Eriodictyol Eriodictyol was suggested by Smith and Smith as
an interfatial inhibitor between the virus S-protein and human
ACE2 receptor [6]. Eriodictyol’s conformations are predominately
determined by a rotatable bond that connects the two ring systems,
and by the envelope conformations adopted by the 4-chromanone
residue. These envelope conformations result in either an overall
bent structure (e.g. conformer 1, ∆E=0.000 kcal·mol−1) or a
more linear structure (e.g. conformer 2, ∆E=0.035 kcal·mol−1;
Figure 1f). The final factor that determines the conformations
are the hydroxyl orientiations. A total of 49 stationary points
were identified at the B97-D3(BJ)/cc-pVTZ theory level, with 16
minima being below a relative energy of 1.2 kcal·mol−1 (Tables 4).
This likely implies that this conformation is highly flexible under
physiological conditions and could easily adopt its conformation
to the topology of the binding sites that it interacts with.
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Figure 1: Geometries of the most stable minima identified using B97-D3(BJ)/cc-pVTZ//B97-D3(BJ)/cc-pVTZ for a) Chloroquine
isomer 1 (*: stereocenter) b) Chloroquine isomer 2 (*: stereocenter), c) Hydroxychloroquine isomer 1, d) Silmitasertib, e) Valproic
acid and f) the two lowest energy conformers of eriodictyol, each representing one of the possible envelope conformations.
3
Table 1: Chloroquine isomer 1’s relative energies
(kcal·mol−1) computed at B97-D3(BJ)/cc-pVTZ//B97-
D3(BJ)/cc-pVTZ theory level.
Conf. ∆E Conf. ∆E Conf. ∆E
1 0.000a 35 8.627 69 10.719
2 1.560a 36 8.627 70 10.785
3 1.958a 37 8.638 71 10.901
4 2.085a 38 8.646 72 10.990
5 3.697 39 8.797 73 11.031
6 4.339 40 8.868 74 11.094
7 4.358 41 9.059 75 11.126
8 4.918 42 9.115 76 11.158
9 5.566 43 9.150 77 11.177
10 5.911 44 9.168 78 11.240
11 6.339 45 9.168 79 11.286
12 6.863 46 9.172 80 11.460
13 7.142 47 9.201 81 11.527
14 7.253 48 9.245 82 11.594
15 7.303 49 9.274 83 11.905
16 7.370 50 9.303 84 11.927
17 7.448 51 9.309 85 11.964
18 7.534 52 9.429 86 11.964
19 7.557 53 9.531 87 11.991
20 7.603 54 9.583 88 12.043
21 7.639 55 9.594 89 12.075
22 7.752 56 9.611 90 12.079
23 7.779 57 9.655 91 12.084
24 7.866 58 10.003 92 12.138
25 7.961 59 10.068 93 12.381
26 8.049 60 10.153 94 12.656
27 8.147 61 10.156 95 13.011
28 8.217 62 10.200 96 13.162
29 8.279 63 10.226 97 13.308
30 8.347 64 10.231 98 13.417
31 8.348 65 10.301 99 13.590
32 8.408 66 10.403 100 13.957
33 8.421 67 10.411 101 14.119
34 8.536 68 10.423 102 14.490
a Frequency analysis confirms that this conformer is
a minimum on the potential energy surface.
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Table 2: Chloroquine isomer 2’s relative energies (kcal·mol−1) computed at B97-D3(BJ)/cc-pVTZ//B97-
D3(BJ)/cc-pVTZ theory level.
Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E
1 0.000a 20 6.489 39 7.740 58 9.072 76 9.913 94 11.440
2 1.048a 21 6.606 40 8.117 59 9.072 77 9.929 95 11.560
3 2.759 22 6.630 41 8.166 60 9.088 78 9.939 96 11.576
4 2.906 23 6.693 42 8.220 61 9.093 79 9.978 97 11.710
5 4.508 24 6.844 43 8.265 62 9.102 80 10.050 98 11.805
6 5.069 25 6.913 44 8.318 63 9.176 81 10.061 99 12.021
7 5.241 26 6.922 45 8.320 64 9.229 82 10.190 100 12.041
8 5.283 27 6.927 46 8.383 65 9.266 83 10.233 101 12.097
9 5.670 28 7.026 47 8.460 66 9.296 84 10.506 102 12.298
10 5.797 29 7.035 48 8.476 67 9.365 85 10.553 103 12.402
11 5.820 30 7.042 49 8.498 68 9.368 86 10.614 104 12.538
12 5.823 31 7.250 50 8.560 69 9.459 87 10.870 105 12.618
13 5.875 32 7.250 51 8.570 70 9.535 88 10.873 106 12.637
14 5.891 33 7.262 52 8.626 71 9.549 89 10.909 107 13.027
15 5.897 34 7.446 53 8.719 72 9.561 90 10.929 108 13.449
16 5.975 35 7.498 54 8.797 73 9.578 91 11.021 109 13.523
17 6.456 36 7.540 55 9.011 74 9.718 92 11.133 110 15.352
18 6.461 37 7.599 56 9.025 75 9.795 93 11.191 111 16.435
19 6.462 38 7.692 57 9.072
a Frequency analysis confirms that this conformer is a minimum on the potential energy surface.
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Table 3: Hydrochloroquine isomer 1’s relative energies (kcal·mol−1) computed at B97-D3(BJ)/cc-pVTZ//B97-
D3(BJ)/cc-pVTZ theory level.
Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E
1 0.000 46 6.271 90 8.027 134 9.353 178 10.535 222 11.849
2 0.400 47 6.315 91 8.043 135 9.373 179 10.544 223 11.863
3 0.988 48 6.325 92 8.052 136 9.394 180 10.595 224 11.900
4 1.440 49 6.381 93 8.063 137 9.395 181 10.618 225 12.072
5 1.603 50 6.426 94 8.083 138 9.401 182 10.740 226 12.134
6 2.162 51 6.477 95 8.105 139 9.413 183 10.770 227 12.166
7 2.165 52 6.571 96 8.118 140 9.517 184 10.779 228 12.192
8 2.213 53 6.610 97 8.136 141 9.525 185 10.810 229 12.222
9 2.320 54 6.634 98 8.170 142 9.548 186 10.872 230 12.236
10 2.431 55 6.644 99 8.196 143 9.591 187 10.878 231 12.261
11 2.448 56 6.665 100 8.264 144 9.622 188 10.901 232 12.276
12 2.615 57 6.733 101 8.334 145 9.655 189 10.938 233 12.353
13 2.681 58 6.748 102 8.372 146 9.740 190 10.954 234 12.367
14 2.707 59 6.853 103 8.398 147 9.745 191 10.958 235 12.371
15 2.858 60 6.856 104 8.416 148 9.786 192 10.963 236 12.376
16 3.105 61 6.986 105 8.422 149 9.791 193 10.969 237 12.413
17 3.357 62 7.151 106 8.447 150 9.792 194 11.006 238 12.465
18 3.499 63 7.191 107 8.596 151 9.820 195 11.040 239 12.533
19 3.508 64 7.250 108 8.609 152 9.833 196 11.072 240 12.580
20 3.768 65 7.284 109 8.641 153 9.836 197 11.118 241 12.607
21 3.844 66 7.296 110 8.680 154 9.874 198 11.176 242 12.785
22 3.845 67 7.297 111 8.680 155 9.884 199 11.176 243 12.868
23 3.848 68 7.418 112 8.710 156 9.891 200 11.209 244 12.904
24 3.888 69 7.419 113 8.725 157 9.907 201 11.221 245 12.911
25 3.952 70 7.473 114 8.806 158 10.005 202 11.249 246 12.975
26 4.057 71 7.473 115 8.822 159 10.021 203 11.253 247 13.129
27 4.263 72 7.505 116 8.839 160 10.033 204 11.255 248 13.169
28 4.334 73 7.507 117 8.863 161 10.051 205 11.274 249 13.199
29 4.356 74 7.542 118 8.873 162 10.052 206 11.282 250 13.283
30 4.411 75 7.590 119 8.877 163 10.075 207 11.330 251 13.322
31 4.453 76 7.592 120 8.907 164 10.085 208 11.338 252 13.414
32 4.794 77 7.593 121 8.973 165 10.107 209 11.352 253 13.428
33 5.024 78 7.675 122 8.980 166 10.142 210 11.372 254 13.482
34 5.228 79 7.736 123 9.010 167 10.149 211 11.390 255 13.537
35 5.298 80 7.749 124 9.046 168 10.294 212 11.414 256 13.721
36 5.337 81 7.752 125 9.067 169 10.297 213 11.440 257 13.771
37 5.475 82 7.763 126 9.105 170 10.320 214 11.523 258 13.802
38 5.743 83 7.775 127 9.136 171 10.331 215 11.534 259 13.907
39 5.771 84 7.819 128 9.172 172 10.335 216 11.541 260 13.956
40 5.862 85 7.859 129 9.273 173 10.463 217 11.630 261 14.359
41 5.887 86 7.868 130 9.277 174 10.468 218 11.641 262 14.416
42 5.938 87 7.880 131 9.299 175 10.494 219 11.688 263 14.629
43 6.034 88 7.962 132 9.308 176 10.505 220 11.696 264 14.660
44 6.114 89 7.994 133 9.353 177 10.529 221 11.826 265 14.826
45 6.183
a Frequency analysis confirms that this conformer is a minimum on the potential energy surface.
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Table 4: Eriodictyol relative energies (kcal·mol−1) computed at B97-D3(BJ)/cc-
pVTZ//B97-D3(BJ)/cc-pVTZ theory level.
1 0.000a 10 0.522a 18 3.565 26 13.786 34 14.555 42 17.254
2 0.035a 11 0.557a 19 3.626 27 13.904 35 14.631 43 17.337
3 0.175a 12 0.692a 20 3.828 28 13.968 36 14.669 44 17.626
4 0.213a 13 0.739a 21 3.900 29 13.998 37 14.698 45 17.665
5 0.284a 14 0.777a 22 3.966 30 14.128 38 14.820 46 17.864
6 0.340a 15 0.805a 23 3.975 31 14.147 39 14.897 47 17.915
7 0.355a 16 1.116a 24 4.233 32 14.185 40 15.238 48 18.192
8 0.407a 17 3.536 25 13.245 33 14.419 41 16.999 49 18.312
9 0.514a
a Frequency analysis confirms that this conformer is a minimum on the potential energy
surface.
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Table 5: Silmitasertib relative energies (kcal·mol−1) computed at B97-
D3(BJ)/cc-pVTZ//B97-D3(BJ)/cc-pVTZ theory level.
Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E
1 0.000a 8 1.749a 15 5.942 21 6.749
2 0.247a 9 1.749a 16 6.588 22 7.324
3 0.431a 10 1.904a 17 6.588 23 7.324
4 1.521a 11 1.904a 18 6.712 24 7.489
5 1.521a 12 5.384 19 6.712 25 7.489
6 1.657a 13 5.384 20 6.749 26 7.520
7 1.657 14 5.942
a Frequency analysis confirms that this conformer is a minimum on
the potential energy surface.
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Table 6: Valproic acid relative energies (kcal·mol−1) computed at B97-D3(BJ)/cc-pVTZ//B97-D3(BJ)/cc-
pVTZ theory level.
Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E
1 0.000a 29 1.534a 57 2.289 85 3.061 113 3.398 141 4.450
2 0.206a 30 1.534a 58 2.289 86 3.082 114 3.537 142 4.450
3 0.206a 31 1.561a 59 2.328 87 3.102 115 3.573 143 4.597
4 0.427a 32 1.561a 60 2.328 88 3.102 116 3.573 144 4.597
5 0.587a 33 1.571a 61 2.388 89 3.138 117 3.582 145 4.710
6 0.643a 34 1.571a 62 2.450 90 3.138 118 3.582 146 4.710
7 0.643a 35 1.604a 63 2.450 91 3.149 119 3.583 147 4.956
8 0.680a 36 1.604a 64 2.498 92 3.149 120 3.608 148 4.956
9 0.680a 37 1.622a 65 2.498 93 3.198 121 3.608 149 5.021
10 0.729a 38 1.622a 66 2.527 94 3.198 122 3.618 150 5.021
11 0.789a 39 1.679a 67 2.527 95 3.202 123 3.762 151 5.095
12 0.789a 40 1.679a 68 2.532 96 3.202 124 3.762 152 5.095
13 0.934a 41 1.681a 69 2.532 97 3.205 125 3.925 153 5.144
14 0.934a 42 1.681a 70 2.574 98 3.205 126 3.925 154 5.144
15 1.010a 43 1.724a 71 2.601 99 3.208 127 4.079 155 5.187
16 1.010a 44 1.724a 72 2.601 100 3.233 128 4.079 156 5.187
17 1.113a 45 1.777a 73 2.603 101 3.238 129 4.131 157 5.225
18 1.113a 46 1.777a 74 2.780 102 3.256 130 4.131 158 5.225
19 1.166a 47 1.835a 75 2.780 103 3.256 131 4.194 159 5.435
20 1.166a 48 1.835a 76 2.806 104 3.328 132 4.194 160 5.435
21 1.197a 49 1.857a 77 2.806 105 3.328 133 4.198 161 5.594
22 1.197a 50 1.857a 78 2.826 106 3.340 134 4.198 162 5.594
23 1.315a 51 1.884a 79 2.826 107 3.340 135 4.382 163 6.072
24 1.315a 52 1.884a 80 2.840 108 3.341 136 4.382 164 6.072
25 1.344a 53 2.012 81 2.907 109 3.341 137 4.416 165 6.732
26 1.344a 54 2.012 82 2.958 110 3.353 138 4.416 166 6.934
27 1.404a 55 2.138 83 2.958 111 3.353 139 4.449 167 6.934
28 1.404a 56 2.138 84 3.000 112 3.353 140 4.449
a Frequency analysis confirms that this conformer is a minimum on the potential energy surface.
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Supplementary Information
Note that the conformation numbers reported in the following supplementary tables do not correspond to the same numbered
conformations reported in the Results and Discussion sections. This is do to a) the fact that the conformations can change when
optimized at different theory level, and b) the lowest energy conformation can also change.
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Table S1: Chloroquine isomer 1’s relative energies
(kcal·mol−1) computed at HF/6-31G(d)//HF/6-31G(d)
theory level.
Conf. ∆E Conf. ∆E Conf. ∆E
1 0.000 40 5.293 79 8.023
2 0.585 41 5.413 80 8.113
3 0.643 42 5.726 81 8.115
4 0.837 43 5.730 82 8.303
5 1.261 44 5.735 83 8.403
6 1.324 45 5.781 84 8.459
7 1.436 46 5.810 85 8.501
8 1.790 47 5.923 86 8.691
9 1.961 48 5.936 87 8.725
10 2.256 49 5.947 88 8.794
11 2.613 50 6.009 89 8.845
12 2.707 51 6.016 90 8.900
13 2.764 52 6.111 91 8.921
14 3.238 53 6.155 92 8.923
15 3.416 54 6.201 93 9.028
16 3.481 55 6.268 94 9.065
17 3.518 56 6.483 95 9.097
18 3.906 57 6.568 96 9.198
19 4.006 58 6.648 97 9.221
20 4.114 59 6.650 98 9.364
21 4.167 60 6.678 99 9.703
22 4.393 61 6.692 100 10.016
23 4.429 62 6.754 101 10.020
24 4.466 63 6.881 102 10.307
25 4.589 64 6.922 103 10.633
26 4.622 65 7.075 104 10.634
27 4.643 66 7.093 105 10.765
28 4.652 67 7.164 106 10.817
29 4.656 68 7.205 107 11.006
30 4.858 69 7.208 108 11.069
31 4.870 70 7.308 109 11.359
32 4.909 71 7.358 110 11.497
33 4.935 72 7.472 111 11.529
34 5.077 73 7.494 112 11.870
35 5.146 74 7.498 113 11.901
36 5.156 75 7.505 114 13.385
37 5.244 76 7.793 115 13.643
38 5.262 77 7.942 116 13.989
39 5.277 78 8.002
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Table S2: Chloroquine isomer 2’s relative energies (kcal·mol−1) computed at HF/6-31G(d)//HF/6-31G(d)
theory level.
Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E Conf. ∆E
1 0.000 20 2.398 39 3.966 58 4.882 76 5.973 94 8.504
2 0.529 21 2.570 40 3.975 59 4.917 77 6.222 95 8.610
3 0.653 22 2.647 41 3.995 60 4.977 78 6.237 96 8.630
4 0.911 23 2.668 42 3.998 61 5.013 79 6.377 97 8.711
5 0.970 24 2.682 43 4.031 62 5.184 80 6.468 98 8.838
6 1.197 25 2.809 44 4.075 63 5.195 81 6.589 99 8.862
7 1.260 26 2.919 45 4.092 64 5.237 82 6.679 100 8.897
8 1.263 27 2.973 46 4.203 65 5.248 83 6.947 101 8.944
9 1.282 28 3.100 47 4.317 66 5.333 84 7.064 102 8.993
10 1.337 29 3.105 48 4.365 67 5.431 85 7.065 103 9.032
11 1.415 30 3.113 49 4.373 68 5.560 86 7.354 104 9.280
12 1.468 31 3.279 50 4.469 69 5.593 87 7.387 105 9.327
13 1.549 32 3.338 51 4.470 70 5.642 88 7.432 106 10.234
14 1.670 33 3.371 52 4.492 71 5.697 89 7.486 107 10.297
15 1.841 34 3.461 53 4.507 72 5.816 90 7.782 108 10.582
16 2.057 35 3.570 54 4.512 73 5.841 91 7.824 109 10.868
17 2.163 36 3.664 55 4.735 74 5.930 92 8.042 110 11.805
18 2.294 37 3.857 56 4.798 75 5.961 93 8.415 111 12.530
19 2.309 38 3.861 57 4.808
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